Acute melanization of silkworm hemolymph by peptidoglycans of the human commensal bacterium Cutibacterium acnes.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 29 06 2022
accepted: 12 09 2022
entrez: 26 9 2022
pubmed: 27 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

Cutibacterium acnes is a pathogenic bacterium that cause inflammatory diseases of the skin and intervertebral discs. The immune activation induced by C. acnes requires multiple cellular responses in the host. Silkworm, an invertebrate, generates melanin by phenoloxidase upon recognizing bacterial or fungal components. Therefore, the melanization reaction can be used as an indicator of innate immune activation. A silkworm infection model was developed for evaluating the virulence of C. acnes, but a system for evaluating the induction of innate immunity by C. acnes using melanization as an indicator has not yet been established. Here we demonstrated that C. acnes rapidly causes melanization of the silkworm hemolymph. On the other hand, Staphylococcus aureus, a gram-positive bacterium identical to C. acnes, does not cause immediate melanization. Even injection of heat-killed C. acnes cells caused melanization of the silkworm hemolymph. DNase, RNase, and protease treatment of the heat-treated C. acnes cells did not decrease the silkworm hemolymph melanization. Treatment with peptidoglycan-degrading enzymes, such as lysostaphin and lysozyme, however, decreased the induction of melanization by the heat-treated C. acnes cells. These findings suggest that silkworm hemolymph melanization may be a useful indicator to evaluate innate immune activation by C. acnes and that C. acnes peptidoglycans are involved in the induction of innate immunity in silkworms.

Identifiants

pubmed: 36155485
doi: 10.1371/journal.pone.0271420
pii: PONE-D-22-18420
pmc: PMC9512201
doi:

Substances chimiques

Melanins 0
Peptidoglycan 0
Monophenol Monooxygenase EC 1.14.18.1
Deoxyribonucleases EC 3.1.-
Ribonucleases EC 3.1.-
Muramidase EC 3.2.1.17
Lysostaphin EC 3.4.24.75

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0271420

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nat Rev Microbiol. 2018 Mar;16(3):143-155
pubmed: 29332945
Mol Microbiol. 2004 Jul;53(2):675-85
pubmed: 15228543
J Biol Chem. 2010 Oct 22;285(43):33338-33347
pubmed: 20702417
PLoS One. 2015 Jul 21;10(7):e0132619
pubmed: 26197393
Br J Dermatol. 2005 Dec;153(6):1105-13
pubmed: 16307644
BMC Med. 2015 Jan 22;13:13
pubmed: 25609421
Nat Chem Biol. 2020 Jan;16(1):24-30
pubmed: 31686030
Prostate. 2013 Jun;73(9):1007-15
pubmed: 23389852
BMC Dermatol. 2013 Sep 06;13:10
pubmed: 24011352
Benef Microbes. 2014 Jun 1;5(2):201-15
pubmed: 24322878
Biol Pharm Bull. 2020;43(2):216-220
pubmed: 32009109
J Endotoxin Res. 2005;11(2):105-11
pubmed: 15949137
Sci Rep. 2019 Jul 1;9(1):9451
pubmed: 31263251
Sci Rep. 2022 May 6;12(1):7464
pubmed: 35523841
Dev Comp Immunol. 2018 Jun;83:3-11
pubmed: 29289612
Annu Rev Immunol. 2007;25:697-743
pubmed: 17201680
Exp Dermatol. 2013 Jun;22(6):386-91
pubmed: 23711061
Microb Pathog. 2002 Apr;32(4):183-90
pubmed: 12079408
PLoS One. 2012;7(12):e51434
pubmed: 23240022
Dev Comp Immunol. 2014 Jan;42(1):16-24
pubmed: 23632253
Cell Rep. 2019 Apr 23;27(4):1050-1061.e3
pubmed: 31018123
Front Microbiol. 2017 Mar 07;8:373
pubmed: 28326075
RSC Adv. 2019 Nov 21;9(65):37889-37894
pubmed: 35541796
J Invest Dermatol. 2016 Mar;136(3):621-630
pubmed: 26739093
J Antibiot (Tokyo). 2021 Jul;74(7):443-449
pubmed: 34045695
FEMS Microbiol Rev. 2008 Mar;32(2):149-67
pubmed: 18194336
Insects. 2021 Jul 08;12(7):
pubmed: 34357279
J Clin Med. 2022 Mar 13;11(6):
pubmed: 35329904
Nat Rev Immunol. 2004 Jul;4(7):499-511
pubmed: 15229469
Drug Discov Ther. 2015 Aug;9(4):238-46
pubmed: 25865526
Lancet. 2001 Jun 23;357(9273):2024-5
pubmed: 11438138
Front Physiol. 2014 Jul 11;5:252
pubmed: 25071597
Drug Discov Ther. 2021;15(3):139-142
pubmed: 34234062
J Appl Glycosci (1999). 2018 Aug 20;65(3):31-36
pubmed: 34354510
J Biol Chem. 1968 Feb 10;243(3):487-96
pubmed: 5637699
Microbiol Immunol. 2020 Sep;64(9):585-592
pubmed: 32757288
Dev Comp Immunol. 2017 Dec;77:307-317
pubmed: 28826989
Microbiol Immunol. 2019 Feb;63(2):41-50
pubmed: 30666711
Microorganisms. 2021 Mar 18;9(3):
pubmed: 33803499
PLoS One. 2011 Mar 30;6(3):e18292
pubmed: 21479175
Spine (Phila Pa 1976). 2015 May 15;40(10):E587-92
pubmed: 25955094

Auteurs

Yasuhiko Matsumoto (Y)

Department of Microbiology, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.

Eri Sato (E)

Department of Microbiology, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.

Takashi Sugita (T)

Department of Microbiology, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH